Drug contract may see advent of CMO

Advanced Search

The story appears on

Page A11

September 3, 2014

GET this page in PDF

Free for subscribers

View shopping cart

Drug contract may see advent of CMO

By Feng Jianmin | September 3, 2014, Wednesday |

Print Edition

GERMANY’S Boehringer Ingelheim yesterday signed an agreement to manufacture biopharmaceuticals for Beijing-based biotech company BeiGene in Shanghai, which has been studying plans to allow contract manufacturing of biomedicine.

BI’s newly invested Zhangjiang facility in Shanghai is expected to start producing cancer drugs for BeiGene next year to be used for clinical research purposes, the companies said. The 500 million yuan (US$81.3 million) facility will eventually become BI’s fourth manufacturing plant to support the global market after Germany, Austria and the US.

Shanghai has been considering since 2013 to be the first in China to introduce biophamaceuticals contract manufacturing organization (CMO), which lets a contract manufacturer act as a producer and shipper on behalf of a hiring company.

Hubertus von Baumbach, member of BI’s board of managing directors, said the firm is confident of a CMO license for the Zhangjiang facility, a joint investment with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co, which started last year.

Business Consumer

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Drug contract may see advent of CMO

Email this to your friend